AbbVie Inc. is a global biopharmaceutical company headquartered in North Chicago, Illinois, United States. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has quickly become one of the largest pharmaceutical companies in the world.

## Company Overview

AbbVie's mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives. The company focuses on several key therapeutic areas:

- Immunology
- Oncology
- Neuroscience
- Eye Care
- Aesthetics
- Other Specialties

AbbVie's product portfolio includes treatments for various conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

## Key Products and Pipeline

AbbVie's flagship product is Humira (adalimumab), which accounted for $14 billion in revenues in 2023, representing 27% of the company's total revenue. Other notable products and pipeline developments include:

- RINVOQ and SKYRIZI for autoimmune diseases
- Emraclidine, a potential breakthrough treatment for schizophrenia and other psychiatric conditions
- A robust neuroscience pipeline with multiple clinical-stage and preclinical candidates

## Recent Developments

AbbVie has been actively expanding its portfolio through strategic acquisitions and partnerships:

- In December 2023, AbbVie announced plans to acquire Cerevel Therapeutics for approximately $8.7 billion, strengthening its neuroscience pipeline
- The company completed the acquisition of Allergan plc in 2019 for about $63 billion, significantly expanding its presence in aesthetics and other therapeutic areas
- In December 2024, AbbVie announced its intention to acquire Nimble Therapeutics for $200 million

## Financial Performance

As of January 2025, AbbVie's key financial metrics include:

- Market Capitalization: $318.26 billion
- Stock Price: $180.1
- Revenue (TTM): $55.53 billion
- Net Income: $5.08 billion

AbbVie is listed on the New York Stock Exchange under the ticker symbol ABBV.

## Research and Development

AbbVie invests heavily in research and development, with a focus on addressing unmet medical needs. The company has:

- Over 3,600 clinical trials
- More than 570 pipeline drugs in development
- A strong emphasis on innovative therapies for psychiatric and neurological disorders

AbbVie's commitment to innovation and its diverse portfolio position it as a leading player in the pharmaceutical industry, with significant growth potential in the coming years.



